Pricing Log in Create free account
Friday 6 November 2026 Export COR’s income statement to Excel — free account

Cencora, Inc.

COR Healthcare Medical Distribution

Cencora, Inc.’s revenue for fiscal 2026 (year ended September 2026) was $337.4 billion, up 5.00% from fiscal 2025.

Revenue
+5.52%
EPS
+258.4%
Free cash flow
−7.81%
Total debt
+47.1%

Quarter to September 2026, against a year earlier

334.13 5.55 −1.63%
Market cap
$64.8B
P/E
18.8×
Fwd P/E
17.5×
Dividend yield
0.71%
F-score
7/9
Altman Z
n/a
Beneish M
−2.59
Dividend safety
70/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cencora, Inc. 8-K filed Nov 4, 2026

Period ended Nov 4, 2026 · Filed · accepted 9:25 AM ET · Document on sec.gov · Filing index

7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

What it says

Cencora completed an operating-model restructuring and will adopt a new reporting structure beginning in the first quarter of fiscal 2027. The company provided unaudited revised segment information for each quarter of fiscal 2026 and 2025 and the fiscal years ended September 30, 2026 and 2025.

  • Pharmaceutical Distribution and Services will include U.S. and international wholesale pharmaceutical distribution and related services.

    U.S. and international wholesale pharmaceutical distribution and related services that support health systems, retail pharmacies, and alternate sites of care. — the 8-K

  • Specialty Pharmaceutical and Provider Services will include specialty distribution, management services organizations, World Courier, logistics services, Innomar and strategic components of PharmaLex.

    The Specialty Pharmaceutical and Provider Services reportable segment will consist of specialty distribution services to physician practices, management services organizations, World Courier and third-party logistics (3PL) services, Innomar and strategic components of PharmaLex. — the 8-K

  • Other is not a reportable segment and includes businesses for which Cencora is exploring strategic alternatives.

    businesses for which the Company is exploring strategic alternatives, including MWI Animal Health, Profarma, and the other components of PharmaLex. — the 8-K